What we do Anthem Biosciences Limited is a leading Indian biotechnology company specializing in contract research, development, and manufacturing of active pharmaceutical ingredients and specialty chemicals for global clients. |
Founded in 2,006 |
Market share Market leader in Indian CRDMO space with rapid revenue growth and strong global presence. |
Problem solved Addresses the need for custom manufacturing and research in drug, agrochemical, and specialty chemical industries specializing in high-value organic and biologic compounds. |
Top clients or who we serve Serves global pharmaceutical companies, innovative biotechs and agrochemical industries mainly B2B clients worldwide. |
Key management Ajay Bhardwaj (Chairman, MD & CEO) |
Our journey and innovations Established in 2006, expanded capacities and technologies including flow chemistry, biologics, and peptides; IPO in 2025 raised Rs. 3395 Cr; continuous R&D and facility expansions. |
Where we operate Primarily India with significant exports to North America, Europe, Rest of Asia and other global markets. |
Top products or what we offer Custom synthesis of specialty organic molecules, biologically active peptides, fermentation products, R&D services and proprietary specialty ingredients. |
Top brands Custom Synthesis Plant, Biological Units, Specialty Ingredients with high global demand and strong margins. |
Raw materials needed Specialty organic compounds, biocatalysts, chemical reagents, raw materials for fermentation and peptide synthesis. |
Raw materials supplier Supplied by global chemical and bioprocess materials companies; partnerships for supply chain optimization. |
Recurring vs cyclical contribution Revenue is predominantly recurring from long-term CRDMO contracts and R&D services, with some cyclical specialty ingredient sales. |
Our industry position Among top Indian CRDMOs with 1000+ Crore revenues milestone achieved; growing global footprint and technology edge. |
Financial highlights FY 2024 revenue Rs. 1844.55 Cr, PAT Rs. 451.26 Cr; strong growth driven by CRDMO and specialty segments with improving margins. |
Geographical revenue split North America 26%, Europe 55%, India 17%, Rest of Asia & Others 2% approximately. |
Order book Strong order pipeline supported by long-term contracts and new clients in biopharma and specialty ingredients. |
Whats driving growth Growth fueled by global pharmaceutical outsourcing trend, investment in green technologies, capacity expansions, and R&D innovation. |
Our future plans Expansion of Unit III, adoption of cutting-edge technologies like photochemistry and electro synthesis, and focus on sustainable manufacturing. |
Our green promise Commitment to renewable energy (89% FY24), zero liquid discharge, low greenhouse emissions, and water recycling initiatives. |
Our people and values Over 2000 scientists and professionals; culture centered on innovation, ethics, and sustainability. |
Key challenges ahead Managing regulatory changes, labor law compliance, enhancing operational efficiencies, and global market competition. |
Interesting facts Fastest Indian CRDMO to reach 1000 Crore revenue by FY21; strong ESG initiatives and nearly 90% renewable power usage. |
Risks and strategy Risk from labor law updates and market fluctuations mitigated by dynamic risk management and diversified client base. |
